Metastatic castration-resistant prostate cancer. Use of cabazitaxel taking into consideration current data

Gschwend JE, Albers P, Boegemann M, Goebell P, Heidenreich A, Klier J, Koenig F, Machtens S, Pantel K, Thomas C (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Urologe Springer Verlag (Germany)

Book Volume: 57

Pages Range: 34-39

Journal Issue: 1

DOI: 10.1007/s00120-017-0533-y

Abstract

Background. At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. Objectives. The focus is on the clinical impact of these data. Materials andmethods. A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data. Results. The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients withmCRPC. Conclusions. Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20mg/m(2) cabazitaxel.

Authors with CRIS profile

Peter Goebell Urologische Klinik

Involved external institutions

Aturo - Fachärzte für Urologie und Andrologie DE Germany (DE) Universitätsklinikum Münster DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) Marien-Krankenhaus Bergisch Gladbach DE Germany (DE) Technische Universität München (TUM) DE Germany (DE) Heinrich-Heine-Universität Düsseldorf DE Germany (DE) Universitätsklinikum Köln DE Germany (DE)

How to cite

APA:

Gschwend, J.E., Albers, P., Boegemann, M., Goebell, P., Heidenreich, A., Klier, J.,... Thomas, C. (2018). Metastatic castration-resistant prostate cancer. Use of cabazitaxel taking into consideration current data. Urologe, 57(1), 34-39. https://doi.org/10.1007/s00120-017-0533-y

MLA:

Gschwend, J. E., et al. "Metastatic castration-resistant prostate cancer. Use of cabazitaxel taking into consideration current data." Urologe 57.1 (2018): 34-39.

BibTeX: Download